<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04688801</url>
  </required_header>
  <id_info>
    <org_study_id>Ajuvant immunotherapy ZYP</org_study_id>
    <nct_id>NCT04688801</nct_id>
  </id_info>
  <brief_title>Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer</brief_title>
  <official_title>Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer With or Without Preoperative Chemotherapy With High Risk for Recurrence (N+ and/ or R1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Second Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Second Hospital of Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Surgery with or without neoadjuvant therapy is usually used as the treatment for resectable&#xD;
      esophageal cancer or esophageal- gastric junction cancer. Patients who have a poor response&#xD;
      to neoadjuvant therapy and have an incomplete (R1) resection or have metastatic lymph nodes&#xD;
      in the resection specimen (N+) are especially at risk of recurrence, to continue with the&#xD;
      chemotherapy± radiotherapy is often used in these cases. However, the overall survival is&#xD;
      still poor. We designed a prospective randomized controlled tial to study whether&#xD;
      immunotherapy could be used with chemotherapy after surgery to improve overall survival. The&#xD;
      primary endpoint ofthe study is disease free survival, with secondary endpoints of overall&#xD;
      survival, safety and toxicity, and quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease free survival rate</measure>
    <time_frame>5 years after surgery</time_frame>
    <description>disease free survival after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival rate</measure>
    <time_frame>5 years after surgery</time_frame>
    <description>overall survival after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>within 6 months</time_frame>
    <description>Rate of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI- CTCAE v5.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life （KPS or PS or QOL or EORTC QLQ C30）</measure>
    <time_frame>5 years after therapy</time_frame>
    <description>Quality of Life （KPS or PS or QOL or EORTC QLQ C30）after therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Gastroesophageal Cancer</condition>
  <condition>Immunotherapy</condition>
  <condition>Adjuvant</condition>
  <arm_group>
    <arm_group_label>Chemotherapy± Radiotherapy Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemotherapy± Radiotherapy is used as adjuvant therapy for high risk patients after surgery with or without neoadjuvant therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy + Immunotherapy ± Radiotherapy Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy + Immunotherapy ± Radiotherapy is used as adjuvant therapy for high risk patients after surgery with or without neoadjuvant therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy Drugs, Cancer</intervention_name>
    <description>Chemotherapy± Radiotherapy after surgery</description>
    <arm_group_label>Chemotherapy± Radiotherapy Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunotherapy</intervention_name>
    <description>Chemotherapy + Immuonotherapy ± Radiotherapy after surgery</description>
    <arm_group_label>Chemotherapy + Immunotherapy ± Radiotherapy Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Histologically proven esophageal or EG-junction carcinoma (Siewert I-II). The heart and&#xD;
        lung function can tolerate surgery. The cancer is resectable and incurable therapy will be&#xD;
        perfomed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        EG-junction carcinoma (Siewert III). M1 stage according to the current (8th) version of&#xD;
        TNMclassification system. The heart and lung function can't tolerate surgery. R2 Resection&#xD;
        Status.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yunpeng Zhao, Doc.</last_name>
    <phone>+8617660081916</phone>
    <phone_ext>17660081916</phone_ext>
    <email>zhaoyunpengsddx@sdu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250033</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunpeng Zhao, doctor</last_name>
      <phone>+8618766188692</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>December 25, 2020</last_update_submitted>
  <last_update_submitted_qc>December 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antineoplastic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

